Advanced Pipeline
| Product / Indication | Pre Clinical | Phase 1 | Phase 2 | Phase 3 | Approved |
|---|---|---|---|---|---|
BCDA-01 : CardiAMP Cell TherapyIndication : Ischemic Heart Failure |
|
||||
BCDA-02 : CardiAMP Cell TherapyIndication : Chronic Myocardial Ischemia with Refractory Angina |
|
||||
BCDA-03 CardiALLO Cell TherapyIndication : Ischemic Heart Failure |
|
||||
Helix Partner 01: CellProtheraIndication: Acute Infarction |
Funded by Partner |
||||
Helix Partner-02 : Univ of MilanIndication : Heart Failure |
Funded by partner |
||||
- CardiAMP – autologous minimally processed bone marrow cells (a patient’s own cells)
- CardiALLO –allogenic culture expanded mesenchymal stem cells derived from bone marrow (donor-derived)
Both programs provide compelling and synergistic approaches to replicating the natural response of bone marrow cells to cardiac injury. CardiAMP harnesses the potential of autologous minimally processed bone marrow cells, using a pre-procedure screening test to identify patients most likely to benefit from the therapy. CardiALLO utilizes younger, universal donor mesenchymal stem cells and may be appropriate for patients who are not optimal candidates for the CardiAMP therapy.
News
04 Mar
Henry Ford Health System
Henry Ford Health System Studies Novel Cell Therapy Aimed at Improving Heart Failure Symptoms
08 Feb
15 Sep
03 Aug
Pharmaceutical Technology
BioCardia’s novel CardiAMP stem cell therapy closer to approval in heart failure
28 Jul
10 Jan
press releases
30 Mar Have questions?
CALL US NOW
CALL US NOW
: (800) 624-1179
Have questions?
EMAIL US NOW
EMAIL US NOW
: info@biocardia.com
biocardia takes a new and comprehensive
approach to heart failure
By introducing patient screening and highly-efficient delivery to stem cell therapy, the company seeks to increase the likelihood of treatment success, enabling more patients to return to the things they love.